WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:5000; Not yet tested in other applications.
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Specificity
Phospho-KIR5.1 (S416) Polyclonal Antibody detects endogenous levels of KIR5.1 protein only when phosphorylated at S416.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):MEsQM
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Storage
-15°C to -25°C/1 year(Do not lower than -25°C)
Concentration
1 mg/ml
MW(Observed)
48kD
Modification
Phospho
Clonality
Polyclonal
Isotype
IgG
Related Products
Secondary Antibodies
Goat Anti Mouse IgG(H+L) (HRP)
RS0001
More→
Secondary Antibodies
Goat Anti Rabbit IgG(H+L) (HRP)
RS0002
More→
Primary Antibodies
β-actin (PTR2364) Mouse mAb
YM3028
More→
Primary Antibodies
GAPDH (PTR2304) Mouse mAb
YM3029
More→
Antigen&Target Information
Immunogen:
The antiserum was produced against synthesized peptide derived from mouse Kir5.1 around the phosphorylation site of Ser417. AA range:369-418
show all
Specificity:
Phospho-KIR5.1 (S416) Polyclonal Antibody detects endogenous levels of KIR5.1 protein only when phosphorylated at S416.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):MEsQM
KCNJ16 (Potassium Voltage-Gated Channel Subfamily J Member 16) is a Protein Coding gene. Diseases associated with KCNJ16 include sesame syndrome and body dysmorphic disorder. Among its related pathways are Transmission across Chemical Synapses and Inwardly rectifying K+ channels. GO annotations related to this gene include inward rectifier potassium channel activity. An important paralog of this gene is KCNJ3. nward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. KCNJ16 may be involved in the regulation of fluid and pH balance. In the kidney, together with KCNJ10, mediates basolateral K(+) recycling in distal tubules; this process is critical for Na(+) reabsorption at the tubules (PubMed: 24561201). he inward-rectifier potassium channel family (also known as 2-TM channels) include the strong inward-rectifier channels (Kir2. ), the G-protein-activated inward-rectifier channels (Kir3. ) and the ATP-sensitive channels (Kir6. ), which combine with sulphonylurea receptors.